IAM Advisory LLC Has $1.48 Million Stock Holdings in Novartis AG (NYSE:NVS)

IAM Advisory LLC grew its position in Novartis AG (NYSE:NVS) by 1.7% in the 4th quarter, according to its most recent filing with the SEC. The firm owned 15,160 shares of the company’s stock after buying an additional 247 shares during the period. IAM Advisory LLC’s holdings in Novartis were worth $1,475,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Fisher Asset Management LLC boosted its stake in Novartis by 15.7% in the third quarter. Fisher Asset Management LLC now owns 1,706,009 shares of the company’s stock valued at $196,225,000 after acquiring an additional 231,851 shares during the last quarter. FMR LLC lifted its stake in shares of Novartis by 5.5% in the 3rd quarter. FMR LLC now owns 1,353,412 shares of the company’s stock valued at $155,669,000 after purchasing an additional 70,314 shares during the period. Natixis Advisors LLC boosted its position in shares of Novartis by 2.9% in the 3rd quarter. Natixis Advisors LLC now owns 938,844 shares of the company’s stock worth $107,986,000 after purchasing an additional 26,317 shares during the last quarter. Bank of Montreal Can grew its stake in shares of Novartis by 18.7% during the third quarter. Bank of Montreal Can now owns 780,980 shares of the company’s stock worth $90,289,000 after purchasing an additional 123,077 shares during the period. Finally, Canada Pension Plan Investment Board bought a new stake in Novartis in the second quarter valued at about $64,610,000. Institutional investors own 13.12% of the company’s stock.

Analyst Ratings Changes

A number of equities analysts have issued reports on NVS shares. HSBC cut Novartis from a “hold” rating to a “reduce” rating in a report on Wednesday, December 4th. Erste Group Bank reissued a “hold” rating on shares of Novartis in a research note on Tuesday, November 19th. Finally, BMO Capital Markets upped their target price on shares of Novartis from $118.00 to $120.00 and gave the company a “market perform” rating in a research note on Wednesday, October 30th. Two equities research analysts have rated the stock with a sell rating and seven have given a hold rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Hold” and an average price target of $121.50.

Novartis Price Performance

NYSE NVS opened at $97.51 on Friday. The company has a debt-to-equity ratio of 0.55, a quick ratio of 0.90 and a current ratio of 1.11. Novartis AG has a 52-week low of $92.35 and a 52-week high of $120.92. The business has a 50 day simple moving average of $100.61 and a 200 day simple moving average of $108.99. The stock has a market cap of $199.30 billion, a price-to-earnings ratio of 11.32, a PEG ratio of 1.36 and a beta of 0.57.

Novartis (NYSE:NVS) last issued its quarterly earnings data on Tuesday, October 29th. The company reported $2.06 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.94 by $0.12. The company had revenue of $12.82 billion during the quarter, compared to the consensus estimate of $12.62 billion. Novartis had a net margin of 35.96% and a return on equity of 34.80%. During the same quarter in the prior year, the firm earned $1.74 earnings per share. Analysts anticipate that Novartis AG will post 7.63 earnings per share for the current fiscal year.

About Novartis

Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. The company offers prescription medicines for patients and physicians. It focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, and oncology, as well as ophthalmology and hematology.